Analysis of 394 COVID-19 cases infected with Omicron variant in Shenzhen: impact of underlying diseases to patient’s symptoms
The emergence of new variants of SARS-CoV-2 is continuously posing pressure to the epidemic prevention and control in China. The Omicron variant of SARS-CoV-2 having stronger infectivity, immune escape ability, and capability causing repetitive infection spread to many countries and regions all over...
Saved in:
Published in | European journal of medical research Vol. 27; no. 1; pp. 291 - 8 |
---|---|
Main Authors | , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
BioMed Central Ltd
15.12.2022
BioMed Central BMC |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | The emergence of new variants of SARS-CoV-2 is continuously posing pressure to the epidemic prevention and control in China. The Omicron variant of SARS-CoV-2 having stronger infectivity, immune escape ability, and capability causing repetitive infection spread to many countries and regions all over the world including South Africa, United States and United Kingdom etc., in a short time. The outbreaks of Omicron variant also occurred in China. The aim of this study is to understand the epidemiological characteristics of Omicron variant infection in Shenzhen and to provide scientific basis for effective disease control and prevention.
The clinical data of 394 imported COVID-19 cases infected with Omicron variant from 16 December 2021 to 24 March 2022 admitted to the Third People's hospital of Shenzhen were collected and analyzed retrospectively. Nucleic acid of SARS-CoV-2 of nasopharyngeal swabs and blood samples was detected using 2019-nCoV nucleic acid detection kit. Differences in Ct values of N gene were compared between mild group and moderate group. The specific IgG antibody was detected using 2019-nCoV IgG antibody detection kit. Statistical analysis was done using SPSS software and graphpad prism.
Patients were categorized into mild group and moderate group according to disease severity. The data on the general conditions, underlying diseases, COVID-19 vaccination and IgG antibody, viral load, laboratory examination results, and duration of hospitalization, etc., were compared among disease groups. Mild gorup had higher IgG level and shorter nucleic acid conversion time. Patients with underlying diseases have 4.6 times higher probability to progress to moderate infection.
In terms of epidemic prevention, immunization coverage should be strengthened in the population with underlying diseases. In medical institutions, more attention needs to be paid to such vulnerable population and prevent further deterioration of the disease. |
---|---|
AbstractList | Objectives The emergence of new variants of SARS-CoV-2 is continuously posing pressure to the epidemic prevention and control in China. The Omicron variant of SARS-CoV-2 having stronger infectivity, immune escape ability, and capability causing repetitive infection spread to many countries and regions all over the world including South Africa, United States and United Kingdom etc., in a short time. The outbreaks of Omicron variant also occurred in China. The aim of this study is to understand the epidemiological characteristics of Omicron variant infection in Shenzhen and to provide scientific basis for effective disease control and prevention. Methods The clinical data of 394 imported COVID-19 cases infected with Omicron variant from 16 December 2021 to 24 March 2022 admitted to the Third People's hospital of Shenzhen were collected and analyzed retrospectively. Nucleic acid of SARS-CoV-2 of nasopharyngeal swabs and blood samples was detected using 2019-nCoV nucleic acid detection kit. Differences in Ct values of N gene were compared between mild group and moderate group. The specific IgG antibody was detected using 2019-nCoV IgG antibody detection kit. Statistical analysis was done using SPSS software and graphpad prism. Results Patients were categorized into mild group and moderate group according to disease severity. The data on the general conditions, underlying diseases, COVID-19 vaccination and IgG antibody, viral load, laboratory examination results, and duration of hospitalization, etc., were compared among disease groups. Mild gorup had higher IgG level and shorter nucleic acid conversion time. Patients with underlying diseases have 4.6 times higher probability to progress to moderate infection. Conclusion In terms of epidemic prevention, immunization coverage should be strengthened in the population with underlying diseases. In medical institutions, more attention needs to be paid to such vulnerable population and prevent further deterioration of the disease. Keywords: SARS-CoV-2, Omicron, IgG antibody, COVID-19 vaccine The emergence of new variants of SARS-CoV-2 is continuously posing pressure to the epidemic prevention and control in China. The Omicron variant of SARS-CoV-2 having stronger infectivity, immune escape ability, and capability causing repetitive infection spread to many countries and regions all over the world including South Africa, United States and United Kingdom etc., in a short time. The outbreaks of Omicron variant also occurred in China. The aim of this study is to understand the epidemiological characteristics of Omicron variant infection in Shenzhen and to provide scientific basis for effective disease control and prevention.OBJECTIVESThe emergence of new variants of SARS-CoV-2 is continuously posing pressure to the epidemic prevention and control in China. The Omicron variant of SARS-CoV-2 having stronger infectivity, immune escape ability, and capability causing repetitive infection spread to many countries and regions all over the world including South Africa, United States and United Kingdom etc., in a short time. The outbreaks of Omicron variant also occurred in China. The aim of this study is to understand the epidemiological characteristics of Omicron variant infection in Shenzhen and to provide scientific basis for effective disease control and prevention.The clinical data of 394 imported COVID-19 cases infected with Omicron variant from 16 December 2021 to 24 March 2022 admitted to the Third People's hospital of Shenzhen were collected and analyzed retrospectively. Nucleic acid of SARS-CoV-2 of nasopharyngeal swabs and blood samples was detected using 2019-nCoV nucleic acid detection kit. Differences in Ct values of N gene were compared between mild group and moderate group. The specific IgG antibody was detected using 2019-nCoV IgG antibody detection kit. Statistical analysis was done using SPSS software and graphpad prism.METHODSThe clinical data of 394 imported COVID-19 cases infected with Omicron variant from 16 December 2021 to 24 March 2022 admitted to the Third People's hospital of Shenzhen were collected and analyzed retrospectively. Nucleic acid of SARS-CoV-2 of nasopharyngeal swabs and blood samples was detected using 2019-nCoV nucleic acid detection kit. Differences in Ct values of N gene were compared between mild group and moderate group. The specific IgG antibody was detected using 2019-nCoV IgG antibody detection kit. Statistical analysis was done using SPSS software and graphpad prism.Patients were categorized into mild group and moderate group according to disease severity. The data on the general conditions, underlying diseases, COVID-19 vaccination and IgG antibody, viral load, laboratory examination results, and duration of hospitalization, etc., were compared among disease groups. Mild gorup had higher IgG level and shorter nucleic acid conversion time. Patients with underlying diseases have 4.6 times higher probability to progress to moderate infection.RESULTSPatients were categorized into mild group and moderate group according to disease severity. The data on the general conditions, underlying diseases, COVID-19 vaccination and IgG antibody, viral load, laboratory examination results, and duration of hospitalization, etc., were compared among disease groups. Mild gorup had higher IgG level and shorter nucleic acid conversion time. Patients with underlying diseases have 4.6 times higher probability to progress to moderate infection.In terms of epidemic prevention, immunization coverage should be strengthened in the population with underlying diseases. In medical institutions, more attention needs to be paid to such vulnerable population and prevent further deterioration of the disease.CONCLUSIONIn terms of epidemic prevention, immunization coverage should be strengthened in the population with underlying diseases. In medical institutions, more attention needs to be paid to such vulnerable population and prevent further deterioration of the disease. Objectives The emergence of new variants of SARS-CoV-2 is continuously posing pressure to the epidemic prevention and control in China. The Omicron variant of SARS-CoV-2 having stronger infectivity, immune escape ability, and capability causing repetitive infection spread to many countries and regions all over the world including South Africa, United States and United Kingdom etc., in a short time. The outbreaks of Omicron variant also occurred in China. The aim of this study is to understand the epidemiological characteristics of Omicron variant infection in Shenzhen and to provide scientific basis for effective disease control and prevention. Methods The clinical data of 394 imported COVID-19 cases infected with Omicron variant from 16 December 2021 to 24 March 2022 admitted to the Third People’s hospital of Shenzhen were collected and analyzed retrospectively. Nucleic acid of SARS-CoV-2 of nasopharyngeal swabs and blood samples was detected using 2019-nCoV nucleic acid detection kit. Differences in Ct values of N gene were compared between mild group and moderate group. The specific IgG antibody was detected using 2019-nCoV IgG antibody detection kit. Statistical analysis was done using SPSS software and graphpad prism. Results Patients were categorized into mild group and moderate group according to disease severity. The data on the general conditions, underlying diseases, COVID-19 vaccination and IgG antibody, viral load, laboratory examination results, and duration of hospitalization, etc., were compared among disease groups. Mild gorup had higher IgG level and shorter nucleic acid conversion time. Patients with underlying diseases have 4.6 times higher probability to progress to moderate infection. Conclusion In terms of epidemic prevention, immunization coverage should be strengthened in the population with underlying diseases. In medical institutions, more attention needs to be paid to such vulnerable population and prevent further deterioration of the disease. The emergence of new variants of SARS-CoV-2 is continuously posing pressure to the epidemic prevention and control in China. The Omicron variant of SARS-CoV-2 having stronger infectivity, immune escape ability, and capability causing repetitive infection spread to many countries and regions all over the world including South Africa, United States and United Kingdom etc., in a short time. The outbreaks of Omicron variant also occurred in China. The aim of this study is to understand the epidemiological characteristics of Omicron variant infection in Shenzhen and to provide scientific basis for effective disease control and prevention. The clinical data of 394 imported COVID-19 cases infected with Omicron variant from 16 December 2021 to 24 March 2022 admitted to the Third People's hospital of Shenzhen were collected and analyzed retrospectively. Nucleic acid of SARS-CoV-2 of nasopharyngeal swabs and blood samples was detected using 2019-nCoV nucleic acid detection kit. Differences in Ct values of N gene were compared between mild group and moderate group. The specific IgG antibody was detected using 2019-nCoV IgG antibody detection kit. Statistical analysis was done using SPSS software and graphpad prism. In terms of epidemic prevention, immunization coverage should be strengthened in the population with underlying diseases. In medical institutions, more attention needs to be paid to such vulnerable population and prevent further deterioration of the disease. The emergence of new variants of SARS-CoV-2 is continuously posing pressure to the epidemic prevention and control in China. The Omicron variant of SARS-CoV-2 having stronger infectivity, immune escape ability, and capability causing repetitive infection spread to many countries and regions all over the world including South Africa, United States and United Kingdom etc., in a short time. The outbreaks of Omicron variant also occurred in China. The aim of this study is to understand the epidemiological characteristics of Omicron variant infection in Shenzhen and to provide scientific basis for effective disease control and prevention. The clinical data of 394 imported COVID-19 cases infected with Omicron variant from 16 December 2021 to 24 March 2022 admitted to the Third People's hospital of Shenzhen were collected and analyzed retrospectively. Nucleic acid of SARS-CoV-2 of nasopharyngeal swabs and blood samples was detected using 2019-nCoV nucleic acid detection kit. Differences in Ct values of N gene were compared between mild group and moderate group. The specific IgG antibody was detected using 2019-nCoV IgG antibody detection kit. Statistical analysis was done using SPSS software and graphpad prism. Patients were categorized into mild group and moderate group according to disease severity. The data on the general conditions, underlying diseases, COVID-19 vaccination and IgG antibody, viral load, laboratory examination results, and duration of hospitalization, etc., were compared among disease groups. Mild gorup had higher IgG level and shorter nucleic acid conversion time. Patients with underlying diseases have 4.6 times higher probability to progress to moderate infection. In terms of epidemic prevention, immunization coverage should be strengthened in the population with underlying diseases. In medical institutions, more attention needs to be paid to such vulnerable population and prevent further deterioration of the disease. Abstract Objectives The emergence of new variants of SARS-CoV-2 is continuously posing pressure to the epidemic prevention and control in China. The Omicron variant of SARS-CoV-2 having stronger infectivity, immune escape ability, and capability causing repetitive infection spread to many countries and regions all over the world including South Africa, United States and United Kingdom etc., in a short time. The outbreaks of Omicron variant also occurred in China. The aim of this study is to understand the epidemiological characteristics of Omicron variant infection in Shenzhen and to provide scientific basis for effective disease control and prevention. Methods The clinical data of 394 imported COVID-19 cases infected with Omicron variant from 16 December 2021 to 24 March 2022 admitted to the Third People’s hospital of Shenzhen were collected and analyzed retrospectively. Nucleic acid of SARS-CoV-2 of nasopharyngeal swabs and blood samples was detected using 2019-nCoV nucleic acid detection kit. Differences in Ct values of N gene were compared between mild group and moderate group. The specific IgG antibody was detected using 2019-nCoV IgG antibody detection kit. Statistical analysis was done using SPSS software and graphpad prism. Results Patients were categorized into mild group and moderate group according to disease severity. The data on the general conditions, underlying diseases, COVID-19 vaccination and IgG antibody, viral load, laboratory examination results, and duration of hospitalization, etc., were compared among disease groups. Mild gorup had higher IgG level and shorter nucleic acid conversion time. Patients with underlying diseases have 4.6 times higher probability to progress to moderate infection. Conclusion In terms of epidemic prevention, immunization coverage should be strengthened in the population with underlying diseases. In medical institutions, more attention needs to be paid to such vulnerable population and prevent further deterioration of the disease. |
ArticleNumber | 291 |
Audience | Academic |
Author | Lu, Hongzhou Liu, Yingxia Wu, Weibo Zhang, Peiyan Peng, Ling Yang, Liang Feng, Shiyan Li, Jianming Cai, Zhao Lin, Yuanlong Chen, Peifen Wang, Fuxiang Yuan, Jing He, Zhiguang |
Author_xml | – sequence: 1 givenname: Peiyan surname: Zhang fullname: Zhang, Peiyan – sequence: 2 givenname: Zhao surname: Cai fullname: Cai, Zhao – sequence: 3 givenname: Zhiguang surname: He fullname: He, Zhiguang – sequence: 4 givenname: Peifen surname: Chen fullname: Chen, Peifen – sequence: 5 givenname: Weibo surname: Wu fullname: Wu, Weibo – sequence: 6 givenname: Yuanlong surname: Lin fullname: Lin, Yuanlong – sequence: 7 givenname: Shiyan surname: Feng fullname: Feng, Shiyan – sequence: 8 givenname: Ling surname: Peng fullname: Peng, Ling – sequence: 9 givenname: Jianming surname: Li fullname: Li, Jianming – sequence: 10 givenname: Jing surname: Yuan fullname: Yuan, Jing – sequence: 11 givenname: Liang surname: Yang fullname: Yang, Liang – sequence: 12 givenname: Fuxiang surname: Wang fullname: Wang, Fuxiang – sequence: 13 givenname: Yingxia surname: Liu fullname: Liu, Yingxia – sequence: 14 givenname: Hongzhou surname: Lu fullname: Lu, Hongzhou |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36522750$$D View this record in MEDLINE/PubMed |
BookMark | eNptksuO0zAUhiM0iBmGeQEWyBISYpPBlzpOWCBV5VZppC64iJ3l2E7rKrE7sTOobOA1eD2ehNNmGFqELF9kf-e3zjn_w-zEB2-z7DHBl4SUxYs4wRiTHFOaY1xRkZN72RnFE5GLkn05OTifZhcxroHGBS1EVT3ITlnBKRUcn2Xfp1612-giCg1i1QTNFp_nr3NSIa2ijcj5xupkDfrq0gotOqf74NGN6p3yCV7Rh5X132C-RK7bKJ12OoM3tm-3zi-RcdHuhVJAG5Wc9enXj58RxW23SaGLj7L7jWqjvbjdz7NPb998nL3Prxbv5rPpVa75hKe80thwDAtRjGlRaWu4YdpU2LACm7oQhmhV44JbBbk1RHFica2p0kwozth5Nh91TVBrueldp_qtDMrJ_UXol1L1yenWSlsTzcuS10pACWlTYc45VawpG2sEt6D1atTaDHVnjYacetUeiR6_eLeSy3AjK8EJJxQEnt8K9OF6sDHJzkVt21Z5G4YooTWci4KzAtCn_6DrMPTQs5Fi5YRW4i-1VJAA9CzAv3onKqeCYVrApxyoy_9QMIyFvoK9Ggf3RwHPDgJWVrVpFUM7JBd8PAafHFbkrhR_fAYAHQGwT4y9be4QguXOz3L0swQ_y72fJWG_AWdY5r4 |
Cites_doi | 10.1016/j.cmet.2020.04.021 10.1016/S1473-3099(20)30831-8 10.1016/j.cytogfr.2021.06.001 10.1136/bmjdrc-2020-001476 10.1056/NEJMoa2034577 10.1016/S0140-6736(21)02835-X 10.1016/S1473-3099(21)00319-4 10.7150/thno.53691 10.1080/22221751.2021.2023329 10.1001/jama.2021.24868 10.1016/S1473-3099(22)00345-0 10.1038/s41586-022-04474-x 10.1016/S1473-3099(21)00681-2 10.1073/pnas.2002589117 10.1056/NEJMoa2203965 10.1016/S1473-3099(21)00462-X 10.1016/j.ijid.2022.04.029 |
ContentType | Journal Article |
Copyright | 2022. The Author(s). COPYRIGHT 2022 BioMed Central Ltd. 2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s) 2022 |
Copyright_xml | – notice: 2022. The Author(s). – notice: COPYRIGHT 2022 BioMed Central Ltd. – notice: 2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s) 2022 |
DBID | AAYXX CITATION NPM 3V. 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU COVID DWQXO FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
DOI | 10.1186/s40001-022-00927-1 |
DatabaseName | CrossRef PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College Coronavirus Research Database ProQuest Central ProQuest Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef PubMed Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition Coronavirus Research Database ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic Publicly Available Content Database PubMed |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 2047-783X |
EndPage | 8 |
ExternalDocumentID | oai_doaj_org_article_eb1c5885ba70472f905552a3f8fed75e PMC9751512 A730261235 36522750 10_1186_s40001_022_00927_1 |
Genre | Journal Article |
GeographicLocations | South Africa China |
GeographicLocations_xml | – name: South Africa – name: China |
GrantInformation_xml | – fundername: Shenzhen Fund for Guangdong Provincial High-level Clinical Key Specialties grantid: SZGSP011 – fundername: Guangdong Natural Science Foundation for Distinguished Young Scholar grantid: 2020B1515020003 – fundername: Shenzhen Science and Technology Program grantid: KQTD20200909113758004 – fundername: ; grantid: SZGSP011 – fundername: ; grantid: 2020B1515020003 – fundername: ; grantid: KQTD20200909113758004 |
GroupedDBID | --- 0R~ 4.4 53G 5GY 5VS 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAYXX ABUWG ACGFS ADBBV ADRAZ ADUKV AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AOIJS BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CITATION DIK EBD EBLON EBS EMOBN F5P FYUFA GROUPED_DOAJ HMCUK HYE IAO IHR IHW INH INR ITC KQ8 M1P M48 OK1 P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RBZ RNS ROL RPM RSV SMD SOJ SV3 UKHRP -A0 3V. ACRMQ ADINQ C24 M~E NPM PMFND 7XB 8FK AZQEC COVID DWQXO K9. PJZUB PKEHL PPXIY PQEST PQUKI PRINS 7X8 5PM PUEGO |
ID | FETCH-LOGICAL-c545t-9c0d50c0d1a33c79ced5d3cd90d360db67d1cab065ea652f1a51e0bc2ac37a533 |
IEDL.DBID | M48 |
ISSN | 2047-783X 0949-2321 |
IngestDate | Wed Aug 27 01:19:56 EDT 2025 Thu Aug 21 18:39:18 EDT 2025 Fri Jul 11 04:16:03 EDT 2025 Fri Jul 25 06:28:14 EDT 2025 Tue Jun 17 21:46:26 EDT 2025 Tue Jun 10 20:30:09 EDT 2025 Thu May 22 21:32:58 EDT 2025 Thu Jan 02 22:53:05 EST 2025 Tue Jul 01 02:25:15 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | COVID-19 vaccine SARS-CoV-2 Omicron IgG antibody |
Language | English |
License | 2022. The Author(s). Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c545t-9c0d50c0d1a33c79ced5d3cd90d360db67d1cab065ea652f1a51e0bc2ac37a533 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
OpenAccessLink | https://www.proquest.com/docview/2755384297?pq-origsite=%requestingapplication% |
PMID | 36522750 |
PQID | 2755384297 |
PQPubID | 2040181 |
PageCount | 8 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_eb1c5885ba70472f905552a3f8fed75e pubmedcentral_primary_oai_pubmedcentral_nih_gov_9751512 proquest_miscellaneous_2755576536 proquest_journals_2755384297 gale_infotracmisc_A730261235 gale_infotracacademiconefile_A730261235 gale_healthsolutions_A730261235 pubmed_primary_36522750 crossref_primary_10_1186_s40001_022_00927_1 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2022-12-15 |
PublicationDateYYYYMMDD | 2022-12-15 |
PublicationDate_xml | – month: 12 year: 2022 text: 2022-12-15 day: 15 |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: London |
PublicationTitle | European journal of medical research |
PublicationTitleAlternate | Eur J Med Res |
PublicationYear | 2022 |
Publisher | BioMed Central Ltd BioMed Central BMC |
Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
References | B Meng (927_CR7) 2022; 603 CNH Commission (927_CR3) 2022; 49 C Maslo (927_CR4) 2022; 327 L Zhu (927_CR18) 2020; 31 B Han (927_CR13) 2021; 21 S Xia (927_CR15) 2022; 22 ME McMenamin (927_CR11) 2022; 22 PB McIntyre (927_CR9) 2022; 399 TM Karpinski (927_CR12) 2021; 11 G Zeng (927_CR16) 2022; 22 FP Polack (927_CR1) 2020; 383 J Wu (927_CR17) 2020 HN Altarawneh (927_CR10) 2022; 387 B Cosar (927_CR2) 2022; 63 S Matsuyama (927_CR5) 2020; 117 H Zhao (927_CR6) 2022; 11 Y Liu (927_CR8) 2022; 120 S Xia (927_CR14) 2021; 21 |
References_xml | – volume: 31 start-page: 1068 issue: 6 year: 2020 ident: 927_CR18 publication-title: Cell Metab doi: 10.1016/j.cmet.2020.04.021 – volume: 21 start-page: 39 issue: 1 year: 2021 ident: 927_CR14 publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(20)30831-8 – volume: 63 start-page: 10 year: 2022 ident: 927_CR2 publication-title: Cytokine Growth Factor Rev doi: 10.1016/j.cytogfr.2021.06.001 – year: 2020 ident: 927_CR17 publication-title: BMJ Open Diabetes Res Care doi: 10.1136/bmjdrc-2020-001476 – volume: 383 start-page: 2603 issue: 27 year: 2020 ident: 927_CR1 publication-title: N Engl J Med doi: 10.1056/NEJMoa2034577 – volume: 399 start-page: 406 issue: 10322 year: 2022 ident: 927_CR9 publication-title: Lancet doi: 10.1016/S0140-6736(21)02835-X – volume: 21 start-page: 1645 issue: 12 year: 2021 ident: 927_CR13 publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(21)00319-4 – volume: 49 start-page: 73 issue: 2 year: 2022 ident: 927_CR3 publication-title: Int J Epidemiol Infect Dis – volume: 11 start-page: 1690 issue: 4 year: 2021 ident: 927_CR12 publication-title: Theranostics doi: 10.7150/thno.53691 – volume: 11 start-page: 277 issue: 1 year: 2022 ident: 927_CR6 publication-title: Emerg Microbes Infect doi: 10.1080/22221751.2021.2023329 – volume: 327 start-page: 583 issue: 6 year: 2022 ident: 927_CR4 publication-title: JAMA doi: 10.1001/jama.2021.24868 – volume: 22 start-page: 1435 issue: 10 year: 2022 ident: 927_CR11 publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(22)00345-0 – volume: 603 start-page: 706 issue: 7902 year: 2022 ident: 927_CR7 publication-title: Nature doi: 10.1038/s41586-022-04474-x – volume: 22 start-page: 483 issue: 4 year: 2022 ident: 927_CR16 publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(21)00681-2 – volume: 117 start-page: 7001 issue: 13 year: 2020 ident: 927_CR5 publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.2002589117 – volume: 387 start-page: 21 issue: 1 year: 2022 ident: 927_CR10 publication-title: N Engl J Med doi: 10.1056/NEJMoa2203965 – volume: 22 start-page: 196 issue: 2 year: 2022 ident: 927_CR15 publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(21)00462-X – volume: 120 start-page: 146 year: 2022 ident: 927_CR8 publication-title: Int J Infect Dis doi: 10.1016/j.ijid.2022.04.029 |
SSID | ssj0000626799 |
Score | 2.3132248 |
Snippet | The emergence of new variants of SARS-CoV-2 is continuously posing pressure to the epidemic prevention and control in China. The Omicron variant of SARS-CoV-2... Objectives The emergence of new variants of SARS-CoV-2 is continuously posing pressure to the epidemic prevention and control in China. The Omicron variant of... Abstract Objectives The emergence of new variants of SARS-CoV-2 is continuously posing pressure to the epidemic prevention and control in China. The Omicron... |
SourceID | doaj pubmedcentral proquest gale pubmed crossref |
SourceType | Open Website Open Access Repository Aggregation Database Index Database |
StartPage | 291 |
SubjectTerms | Acids Analysis Anemia Arthritis Asthma Breast cancer Cardiovascular disease China Coronaviruses COVID-19 vaccine Diabetes Disease transmission Epidemics Epidemiology Fever Glaucoma Health aspects Hospitals Hypertension Hyperthyroidism IgG antibody Immunoglobulin G Infection Infections Laboratories Lymphatic system Medical diagnosis Metastasis Nucleic acids Omicron Pneumonia SARS-CoV-2 Sleep apnea South Africa Statistical analysis Thyroid cancer Tuberculosis Vectors (Biology) |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQDxUXxJtAoUZC4oCixvEr5lZaqoIEPUBRb5ZjO2olNqmatFK5wN_o3-OXMBNnVxtx4IK0u4f1JErmPfHMF0JeybqpIBCD8lZM5iJqlbuSidyD9kRVC6dTg-xndXgsPp7Ik7VXfWFPWIIHTozbAV_iZVXJ2mkENmwMIlSVjjdVE4OWEb0vxLy1Yir54FJpY5ZTMpXa6UUxdg9B7YU4Qzpns0g0Avb_7ZbX4tK8Z3ItCB3cJXem7JHupqu-R27F9j7Z_DTtjz8gP5cYI7RrKDeC7h19-7CfM0M9RKueptarGCg-fqVHC-zGa-kV1MvAYFilX05j-wO-b2kan8Tz4JjZxXcch6LTdk5Ph45OiKy_f930tL9enA_don9Ijg_ef907zKdXLOQeUqchN74IsoAf5jj32vgYZOA-mCJwVYRa6cC8qyFPiU7JsmFOsljUvnSeawep4iOy0XZtfEKo9ioyOBQTAAF8qqAwKqTXQsjaSF1k5M2S3fY8IWnYsQKplE3CsSAcOwrHsoy8Q4msKBEFe_wDdMNOumH_pRsZ2UZ52jRSurJluwtuDaHTuMzI65ECrRnE6t00lAC3hLhYM8qtGSVYoZ8vL3XGTl6gt6WWEE8g4uuMvFwt45HY2dbG7jLRQM0nucrI46Riq5vmwHLE38-IninfjCvzlfbsdMQIN1piLvf0f7DxGbldot0w-MgtsjFcXMbnkIoN9YvR6v4ARm0v3g priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagSIhLxZtAASMhcUBR48SPmAsqhaogQQ9QtDfLcRyKxCbbTYoEF_gb_D1-CTOxszRCQsrmsHZWm3mPPfOZkMeiakpwxCC8JRMp90qmNmc8dSA9XlbcqlAg-04eHvM3C7GIC259LKucbOJoqOvO4Rr5bq4E6CZYT_V8dZriqVG4uxqP0LhILiF0GZZ0qYXarLFkEK0rHeD2uE4heGBT30wpd3uejfVEkI0h8pBK2cw3jRD-_xrqc55qXkV5zi0dXCXbMZ6ke0EArpELvr1OLr-NO-Y3yI8JdYR2DS00p_tHH1-_TJmmDvxXT0Mxlq8pLsjSoyXW57X0K2TQQHIYpe9PfPsdPs9oaKjE38HGs_UXbJCicYOnp0NHI0br75-_etp_W66GbtnfJMcHrz7sH6bx0IXUQTA1pNpltcjgxmxROKWdr0VduFpndSGzupKqZs5WELl4K0XeMCuYzyqXW1coC8HjLbLVdq2_Q6hy0jN4FEMCDnQqIVXKhFOci0oLlSXk6URuswrYGmbMSUppAnMMMMeMzDEsIS-QI5uZiIs9ftGtP5moZgY8jxNlKSqrEAaz0YhnltuiKRtfK-ET8hD5aUKT6Ua7zR4YOgRTK0RCnowzUL-Brc7GNgV4JUTKms3cmc0EvXTz4UlmTLQLvfkrxQl5tBnGJ7HWrfXdWZgDWaAoZEJuBxHbvHQBJEdE_oSomfDNqDIfaT-fjKjhWgmM7u7-_2_dI1dy1AgGl9ghW8P6zN-HsGuoHoy69QdICSkf priority: 102 providerName: ProQuest |
Title | Analysis of 394 COVID-19 cases infected with Omicron variant in Shenzhen: impact of underlying diseases to patient’s symptoms |
URI | https://www.ncbi.nlm.nih.gov/pubmed/36522750 https://www.proquest.com/docview/2755384297 https://www.proquest.com/docview/2755576536 https://pubmed.ncbi.nlm.nih.gov/PMC9751512 https://doaj.org/article/eb1c5885ba70472f905552a3f8fed75e |
Volume | 27 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3da9RAEF9qC-KL-G1qPVcQ-iDRbDa7mwgi19pSD9qK9eTels1mY4Ve0l6uYgX_d2c2ydFgH4S7C9zOJmQ-dmaSmd8S8krkZQqOGJQ3ZSJMnJKhiVkSWtAeJ_PEqLZA9kgeTJPJTMzWSL_dUcfA5sbUDveTmi7O3vy6uPoABv_eG3wq3zZJ5AuDIK1CCCEVQja0AZ5JoaEeduF-uzLHUvktJWMEKFApn_V9NDeeZuCrPKT_vwv3Nc81rKq85qb275G7XXxJx61C3CdrrnpAbh92b9Afkj89CgmtS8qzhO4ef_v0MWQZteDPGtoWZ7mC4gNaejzHer2K_oSMGkQAo_Tk1FW_4fuOtg2WeB5sRFucYcMU7V74NHRZ0w6zdbuhzdX8fFnPm0dkur_3dfcg7LZgCC2EVssws1EhIvhhhnOrMusKUXBbZFHBZVTkUhXMmhziGGekiEtmBHNRbmNjuTIQSj4m61VduaeEKisdg6kYICTApRQSp0hYlSQiz4SKAvK6Z7Y-b5E2tM9QUqlb0WgQjfai0SwgOyiPFSWiZPs_6sV33RmdBj9kRZqK3CgExSwzRDeLDS_T0hVKuIC8QGnqtuV0Zet6DMseQqtxEZBtT4H6B0K1pmtagFtC3KwB5daAEqzUDod7jdG9kutYCfA3EBGogLxcDeNMrHyrXH3Z0kBOKLgMyJNWwVY3zYHliM8fEDVQvQFXhiPVj1OPIZ4pgbHe5n9c9xm5E6NRMPiILbK-XFy65xCJLfMRuaVmakQ2xuPJyQSOO3tHn7-M_HONkTe9v-YdMYo |
linkProvider | Scholars Portal |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3NbtQwELaqVgIuiH9SCjUSiAOKGid2nCAh1F_t0naLoEW9GcdxWiQ2WTZbULnAa_ASPBRPwkycLI2QuFXK5rCerDaef3vmMyFPRFYk4IhBeBMmfG5l7OuQcd-A9Ng441q6AtlRPDjir4_F8QL51fXCYFllZxMbQ51XBtfI10IpQDfBespXk88-nhqFu6vdERpOLHbt-VdI2eqXwy3g79Mw3Nk-3Bz47akCvoFoYeanJshFADemo8jI1Nhc5JHJ0yCP4iDPYpkzozNwzVbHIiyYFswGmQm1iaQWuAAKJn-JAzEYgqWN7dGbt_NVnQDyA5k6gD-e-hCusK5TJ4nXah40FUyQ_yHWkfRZzxs2hwb86xou-MZ-3eYFR7hzg1xvI1i67kTuJlmw5S1yZb_do79Nvnc4J7QqaJRyunnwfrjls5Qa8Jg1deVfNqe4BEwPxlgRWNIvkLMDk2GUvju15Tf4vKCuhRN_B1vdpp-wJYu2W0o1nVW0RYX9_eNnTevz8WRWjes75OhSGHKXLJZVae8TKk1sGTyKQQiHeUogOQuEkZyLLBUy8MjzbrrVxKF5qCYLSmLlmKOAOaphjmIe2UCOzCkRibv5opqeqFaxFfg6I5JEZFoi8GaRIoJaqKMiKWwuhfXIKvJTubbWuT1R62BaEb4tEh551lCgRQG2Gt02RsArITZXj3KlRwmWwPSHO5lRrSWq1V-98cjj-TA-idV1pa3OHA3knSKKPXLPidj8pSOYcjwDwCOyJ3y9WemPlB9PG5zyVAqMJ5f__7dWydXB4f6e2huOdh-QayFqB4NLrJDF2fTMPoSgb5Y9ajWNkg-Xrdx_APhGaLA |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Analysis+of+394+COVID-19+cases+infected+with+Omicron+variant+in+Shenzhen%3A+impact+of+underlying+diseases+to+patient%27s+symptoms&rft.jtitle=European+journal+of+medical+research&rft.au=Zhang%2C+Peiyan&rft.au=Cai%2C+Zhao&rft.au=He%2C+Zhiguang&rft.au=Chen%2C+Peifen&rft.date=2022-12-15&rft.issn=2047-783X&rft.eissn=2047-783X&rft.volume=27&rft.issue=1&rft.spage=291&rft_id=info:doi/10.1186%2Fs40001-022-00927-1&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2047-783X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2047-783X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2047-783X&client=summon |